HANXBIO-B(03378.HK): Research Results of Four Innovative Drugs to Be Presented at AACR 2026

NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) issued a voluntary announcement on April 10, 2026, stating that four innovative drug research results of the Company will be presented in poster format at the AACR 2026 Annual Meeting.
The annual meeting will be held at the San Diego Convention Center, California, USA from April 17 to 22, 2026.
HX044 is a globally innovative CTLA-4/SIRPα bifunctional fusion protein, representing a next-generation CTLA-4 targeted therapy, mainly developed for PD-1/ICI-resistant solid tumors.
HX116 is a potential first-in-class bispecific antibody-drug conjugate (BsAb ADC) targeting PD-L1×VEGF.
HX112 is a novel PD-L1 targeted ADC intended for the treatment of pan-solid tumors.
In addition, the Company will also showcase a 3D tumor organoid ADC evaluation system, verifying that it can better predict the in vivo anti-tumor efficacy of drugs compared with 2D cells.
The selected results further validate the Company’s R&D and innovation capabilities.
The Company reminds that the relevant products may not ultimately be successfully developed and commercialized.
Shareholders and investors should exercise caution when dealing in the Company’s shares.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.